Obstructive laryngotracheitis secondary to gentian violet exposure.
Baca
D
D
Pediatric Residency Program of Thomas Jefferson University/A.I. duPont Hospital for Children, Wilmington, Delaware, USA.
Drexler
C
C
Cullen
E
E
D000891:Anti-Infective Agents, Local / Q000009:adverse effects*; D000935:Antifungal Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000188:drug therapy*; D005260:Female; D005840:Gentian Violet / Q000009:adverse effects*; D006801:Humans; D007231:Infant, Newborn; D007827:Laryngitis / Q000139:chemically induced*; D009761:Nystatin / Q000627:therapeutic use; D014136:Tracheitis / Q000139:chemically induced*
D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents; D009761:Nystatin; D005840:Gentian Violet